be a potential hazard for invading species. Avian malaria should therefore be considered a threat for exotic parrots in Europe until results of further epidemiologic and experimental studies are available. Because many European bird species have been introduced to the native range of the psittacines studied here, a concern has been expressed that these parasites already have become established in these areas and are affecting the natural populations.

Philipp Olias, Maria Wegelin, Wolfgang Zenker, Sabrina Freter, Achim D. Gruber, and Robert Klopfleisch

Author affiliations: Freie Universität, Berlin, Germany (P. Olias, S. Freter, A.D. Gruber, R. Klopfleisch); IDEXX Diavet Labor, Bäch, Switzerland (M. Wegelin); and Animal Clinic Neuwiesen, Uster, Switzerland (W. Zenker)

DOI: 10.3201/eid1705.101618

References


Address for correspondence: Philipp Olias, Department of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, 14163 Berlin, Germany; email: olias.philipp@vetmed.fu-berlin.de

Fatal Human Case of Western Equine Encephalitis, Uruguay

To the Editor: The genus Alphavirus (family Togaviridae) comprises 29 viral species (1), grouped in at least 7 antigenic complexes by their serologic cross-reactivity (2). They are maintained in nature through enzootic cycles involving arthropods as vectors with subsequent amplification in small mammals or birds, and epizootic cycles between mosquitoes and large mammals such as horses or humans.

Few reports have been made of the circulation of alphaviruses in Uruguay. A serologic study conducted in 1970 found antibodies to western (WEEV) and eastern equine encephalitis viruses by using complement fixation and hemagglutination inhibition tests in serum specimens from children (3). In 1972–1973, epizootics in horses caused by WEEV were reported in Argentina and Uruguay, and WEEV was isolated from a sick horse (4).

We report a fatal case of viral encephalitis in April 2009 in Montevideo, Uruguay, in a previously healthy 14-year-old boy. Four days before he sought treatment, he had fever, asthenia, and headaches. At hospital admission (April 12, 2009), he was febrile and without neurologic signs; amoxicillin treatment was initiated. Results of a computed tomography scan of the brain were normal.

On day 1, headache, vomiting, neck stiffness, and partial left seizures on the left side developed. Also exhibited were consciousness depression (Glasgow Coma Scale 12 points), hyperreflexia, and bilateral Babinski sign. A cerebrospinal fluid (CSF) sample was negative for bacteria in cultures. An electroencephalogram showed diffuse brain suffering. The patient was brought to the intensive care unit with a clinical diagnosis of viral encephalitis. Over the next 24–36 hours, intracranial hypertension developed, and medical treatment was given (sedation, hyperventilation, mannitol, and barbiturates). Consciousness depression progressed to a deeper level, and a computed tomography scan of the brain showed dilatation of the temporal ventricles and compression of the peritroncal and sylvian cisterns. During the next 48 hours, the coma level went deeper, reaching 6 on the Glasgow Scale. Another CSF specimen was taken, and PCR results were negative for herpesvirus and enterovirus. Glasgow Coma Scale level was 3 on April 15, and a decompressive craniectomy was done. Seventy-two hours after admission, the patient died.
The patient’s plasma and CSF were tested for antibodies to dengue and West Nile viruses (immunoglobulin M and G) through ELISA (Focus Technologies, Cypress, CA, USA) and for St. Louis encephalitis and dengue virus by M antibody-capture–ELISA (5). RNA was extracted from plasma and CSF, followed by a generic nested reverse transcription–PCR (RT-PCR) for flaviviruses (6). Serologic and molecular test results were negative for the above-mentioned pathogens. Then we performed a generic nested RT-PCR (7), which amplifies 448 bp at first round and 195 bp (second round) of the alphavirus NSP4 gene. Also, a heminested PCR was done (products 372 bp and 303 bp); RNA from Venezuelan equine encephalitis virus Tc-83 (provided by M. Contigiani, Universidad de Córdoba) was used as positive control. The target region is informative enough to allow the precise identification of the most relevant alphaviruses by sequencing and phylogenetic analysis. Alphavirus genome amplification was achieved for the CSF specimen collected at admission to the hospital. Plasma and a second CSF specimen were PCR negative. To confirm these findings, another nested RT-PCR reaction targeting the NSP1 gene was done as described previously (8). A 208-bp amplicon, which corresponded to the expected size for WEEV, was obtained from plasma and the first CSF specimen.

Sequence analyses were conducted on the NSP4 fragments. Maximum likelihood (9) and Bayesian (10) phylogenetic analyses gave similar results. The Figure, panel A, shows that sample LCR/09-303 is part of a well-supported clade (aLRT = 0.99), which groups WEEVs. The sequence LCR/09-303 is a sister taxon to sequences GQ287641 and GQ287642, with poor support (Figure, panel B) (online Appendix Table, www.cdc.gov/EID/content/17/5/952-appT.htm). These are reference WEEV USA strains (Imperial and Kern) obtained from Culex tarsalis mosquitoes. Our sample and the mentioned sequences are part of a well-supported clade (aLRT = 0.85), together with GQ287645, AF214040, and FJ786260. These are also USA strains; 2 were isolated from infected...
horses and 1 from *Cx. tarsalis* mosquitoes. Notably, our sequence is distantly related to GQ287646, which was isolated from *Culex* spp. mosquitoes in Chaco, Argentina. The nucleotide sequence of the positive control VEEV-Tc83 is correctly placed in the VEEV clade.

Clinical and laboratory findings showed that the illness described here was compatible with viral encephalitis. Using a generic RT-PCR assay on an early CSF sample, we amplified a partial sequence (NSP4 gene) of an alphavirus. Phylogenetic analyses showed that the patient’s sequence grouped with sequences from WEEV, with high statistical support. A second RT-PCR assay on the NSP1 gene enabled us to obtain an amplification of 208 bp, which is consistent with the expected size for WEEV. Therefore, we concluded that the fatal disease was likely caused by WEEV. Since the 1970s, to our knowledge, the presence of WEEV (or other alphaviruses) in Uruguay has not been documented. Moreover, no recent reports have been made of genome detection of WEEV in encephalitis cases in the region.

Although the case described here may be rare, the etiology of many viral encephalitides in Uruguay remains unknown. Serologic studies in horses and studies to detect arboviruses in mosquito populations are being conducted to investigate the status of arbovirus infections in Uruguay.

**Acknowledgments**

We thank José C. Russi for his invaluable scientific advice and encouragement during all the stages of this work and Gabriela Algorta for her help and interest in our research.

Adriana Delfraro, Ana María Burguño, Noelia Morel, Gabriel González, Alicia García, Juan Morelli, Walter Pérez, Héctor Chiparelli, and Juan Arbiza

Author affiliations: Universidad de la República, Montevideo, Uruguay (A. Delfraro, A. Burguño, J. Arbiza); Ministerio de Salud Pública, Montevideo (N. Morel, H. Chiparelli); and Hospital Británico, Montevideo (G. González, A. García, J. Morelli, W. Pérez).

DOI: 10.3201/eid1705.101068

**References**


Address for correspondence: Adriana Delfraro, Sección Virologia, Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo, Uruguay; email: adriana@fcien.edu.uy

---

**Widespread Availability of Artemisinin Monotherapy in the United States**

To the Editor: Artemisinin-based combination therapies are recommended as first line treatments for *Plasmodium falciparum* malaria in most areas of the world. The article by Shahinas et al. (1) describes a patient who had *P. falciparum* malaria after returning from Nigeria. Her isolate had an elevated 50% inhibitory concentration to artemisinin derivatives. She had obtained artemesunate in Nigeria and took it weekly for malaria prophylaxis, which might have contributed to the relative resistance found.

In 2009, one artemisinin-based combination therapy (artemether/lumefantrine) became available for use in the United States. However, it is not widely appreciated that artemisinin is actually available in the United States as an herbal supplement for over-the-counter purchase (2). It is marketed for general health maintenance and for treatment of parasitic infections and cancers (Figure), although as with other supplements it is not intended to diagnose, treat, cure, or prevent any disease. As in the patient described by Shahinas et al., widespread use